[ad_1]
A great day for science and humanity. This is what Dr. Albert Burla, president and CEO of the company, said. PfizerA tribute to the results of the experiment, after the Corona virus vaccine that Pfizer is developing has shown its effectiveness by 90%, according to the site.CNBCAmerican.
The giant American pharmaceutical company announced Pfizer And a German biotech company BioNTech Your coronavirus vaccine is more than 90% effective in preventing HIV COVID-19 Among those without evidence of a prior injury, they hailed the development as a “great day for science and humanity.”
Two companies have announced Pfizer Y BioNTech Recently, dividing the case between those vaccinated and those who received a placebo, indicates that the efficacy rate of the vaccine is greater than 90% seven days after the second dose, which means that the protection against COVID-19 It is achieved 28 days after the initial vaccination, which consists of a two-dose schedule.
The president of the company said Pfizer And its CEO is Dr. Albert Mockery of Meg Terrell from CNBC In a show Screech box: “I think we can see the light at the end of the tunnel.”
This comes as drug manufacturers and research centers around the world are scrambling to provide a safe and effective vaccine in a bid to end the Corona virus pandemic that has killed more than 1.25 million. of people around the world.
Scientists hope to have a coronavirus vaccine that is at least 75% effective, while White House coronavirus adviser Dr. Anthony Fauci previously said a vaccine that is 50% or 60% effective would be acceptable. .
The results were based on the first interim efficacy analysis conducted by an independent external data control panel from the Phase 3 clinical study. A group of independent experts oversees clinical trials in the US to ensure the safety of participants .
The analysis evaluated 94 confirmed infections with COVID-19 Among the participants of the experiment amounted to 43,538 participants. Two companies said Pfizer Y BioNTech Division of the condition between vaccinated individuals and those receiving placebo indicates that the vaccine efficacy rate is greater than 90% seven days after the second dose.
This means that protection against COVID-19 It is achieved 28 days after the initial vaccination, which consists of a two-dose schedule.
The final efficacy percentage of the final vaccine may vary as additional and safety data continue to be collected.
Burla said in a statement: “The first set of results from a vaccine trial COVID-19 For the third stage, it provides preliminary evidence of the ability of our vaccine to prevent COVID-19“.
Burla continued: “We have reached this critical milestone in our vaccine development program at a time when the world needs it most, as infection rates have set new records, hospitals are reaching full capacity and economies are they are fighting to reopen. “
“With today’s news, we are approaching an important step in giving people around the world a much-needed breakthrough to help end this global health crisis. We look forward to sharing additional efficacy and safety data generated by thousands of participants in the next few weeks. “
Company said Pfizer Y BioNTech Nearly 42% of the global trial participants have ethnic and diverse backgrounds, adding that no serious safety concerns have been reported so far.
The companies said they plan to submit an emergency use permit to the U.S. Food and Drug Administration shortly after it obtained two months of data, which is currently on its way for the third week of November.
According to current projections, two companies expect Pfizer Y BioNTech Production of up to 50 million doses of vaccine in 2020 and up to 1.3 billion doses in 2021.
The companies said they plan to submit data from the trial’s third full phase, which began July 27, for scientific publication and peer review.
US officials and scientists hope it is a vaccine to prevent COVID-19 Ready in the first half of 2021: 12 to 18 months since scientists first identified the coronavirus and mapped its genetic sequence.
